Clincosm LogoSign in Get a demo

nsclc

Showing 1 - 25 of 360
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Efficacy of Targeted Therapy for NSCLC

Recruiting
  • Evaluation
  • +2 more
  • RecistTM criteria
  • Chongqing, Chongqing, China
    Cancer Center, Dapping Hospital, Army Medical Center of PLA
Nov 15, 2023

Online Adaptive Radiotherapy UsingNovel Linear Accelerator

Recruiting
  • Prostate Cancer
  • +8 more
  • Online adaptive radiation therapy
  • Berlin, Germany
    Charité - Universitätsmedizin
Oct 30, 2023

NSCLC Trial in Suzhou (Envafolimab Injection)

Recruiting
  • NSCLC
  • Envafolimab Injection
  • Suzhou, Jiangsu, China
    Northern Jiangsu People's Hospital
Oct 29, 2023

NSCLC, Breast Cancer, HNSCC Trial in Chang chun (YL202 should be intravenously infused)

Not yet recruiting
  • NSCLC
  • +3 more
  • YL202 should be intravenously infused
  • Chang chun, Jilin, China
    Jilin Provincial Cancer Hospital
Oct 25, 2023

NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

Recruiting
  • NSCLC
  • NK510
  • Tislelizumab，atezolizumab or sugemalimab
  • Nanjing, Jiangsu, China
    General Hospital of Eastern Theater Command
Oct 23, 2023

NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

Recruiting
  • NSCLC
  • EGFR Gene Mutation
  • neo-antigen vaccine
  • Nanjing, China
    The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023

NSCLC Trial in Worldwide (BMS-986315, Nivolumab, Pemetrexed)

Not yet recruiting
  • NSCLC
  • Boise, Idaho
  • +12 more
Oct 17, 2023

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

NSCLC Trial in Beijing

Recruiting
  • NSCLC
    • Beijing, China
      Yuyan Wang
    Oct 10, 2023

    NSCLC Trial in Singapore (Afatinib 40 MG)

    Not yet recruiting
    • NSCLC
    • Afatinib 40 MG
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2023

    Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)

    Not yet recruiting
    • Solid Tumor, Adult
    • +19 more
    • A2B694
    • xT CDx with HLA-LOH Assay
    • Duarte, California
    • +9 more
    Sep 22, 2023

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    NSCLC Trial in China (HSK40118)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +11 more
    Sep 18, 2023

    Single Cell Mutations inPanel of Known Oncogenes in NSCLC

    Recruiting
    • NSCLC
    • Tapestry technology
    • Monza, MB, Italy
      Fondazione IRCCS San Gerardo dei Tintori
    Sep 15, 2023

    NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Fairfax, Virginia
      NEXT Virginia
    Sep 18, 2023

    NSCLC Trial in China (BBP-398, osimertinib)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +4 more
    Sep 4, 2023

    NSCLC Trial in Guangzhou (Neratinib tablets)

    Not yet recruiting
    • NSCLC
    • Neratinib tablets
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 1, 2023

    NSCLC Trial in Nanchang, Shanghai (KN046 plus Axitinib)

    Recruiting
    • NSCLC
    • KN046 plus Axitinib
    • Nanchang, Jiangxi, China
    • +1 more
    Aug 27, 2023

    NSCLC, Mesothelioma, Thymoma Trial in Breda, Dordrecht (Folinic acid)

    Recruiting
    • NSCLC
    • +2 more
    • Folinic acid
    • Breda, Noord Brabant, Netherlands
    • +1 more
    Aug 17, 2023

    NSCLC Trial in Changsha (BEBT-109)

    Completed
    • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 20, 2023

    NSCLC Trial (99mTc-H7ND SPECT/CT imaging performed)

    Not yet recruiting
    • NSCLC
    • 99mTc-H7ND SPECT/CT imaging performed
    • (no location specified)
    Aug 17, 2023

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    Non Small Cell Lung Cancer, NSCLC, Lung Cancer Trial in Port Saint Lucie, Greenville (BL-B01D1)

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Port Saint Lucie, Florida
    • +1 more
    Aug 11, 2023

    Lung Cancer, NSCLC, Brain Metastases Trial (Alectinib, Stereotactic Radiosurgery)

    Not yet recruiting
    • Lung Cancer
    • +2 more
    • (no location specified)
    Aug 4, 2023

    Central Nervous System Metastatic EGFR Mutation Positive NSCLC

    Not yet recruiting
    • NSCLC
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Aug 6, 2023